Last reviewed · How we verify
Accelerated 30 minutes-infusion — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Accelerated 30 minutes-infusion (Accelerated 30 minutes-infusion) — Asan Medical Center. This drug works by inhibiting the PD-1 receptor, which is involved in immune suppression.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Accelerated 30 minutes-infusion TARGET | Accelerated 30 minutes-infusion | Asan Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Accelerated 30 minutes-infusion CI watch — RSS
- Accelerated 30 minutes-infusion CI watch — Atom
- Accelerated 30 minutes-infusion CI watch — JSON
- Accelerated 30 minutes-infusion alone — RSS
Cite this brief
Drug Landscape (2026). Accelerated 30 minutes-infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/accelerated-30-minutes-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab